Synapse - Ross Levine

Results (774)

2-Hydroxyglutarate in IDH mutant AML: Predicting patient responses, minimal residual disease and correlations with methylcytosine and hydroxymethylcytosine levels

Meeting Abstract

Pollyea, D. A.; Kohrt, H. E.; Zhang, B.; Zehnder, J. L.; Schenkein, D. P.; Fantin, V.; Straley, K.; Vasanthakumar, A.; Abdel-Wahab, O.; Levine, R. L.; more...
Blood (2011)

Fulltext@MSK | Save

FTY720 restores PP2A tumor suppressor activity in polycythemia vera CD34(+) progenitors through inhibition of jak2 V617F-and PI-3K gamma-dependent SET serine phosphorylation and enhancement of NOS-dependent PP2A tyrosine nitration

Meeting Abstract

Oaks, J. J.; Mukhopadhyay, A.; Santhanam, R.; Saddoughi, S. A.; Neviani, P.; Harb, J. G.; Ogretmen, B.; Bittman, R.; Levine, R. L.; Quintas-Cardama, A.; more...
Blood (2011)

Fulltext@MSK | Save

Evaluating clonal dominance in a murine knock-in model of jak2V617F MPN

Meeting Abstract

Mullally, A.; Poveromo, L.; Brumme, K.; Al-Shahrour, F.; Lane, S. W.; Shih, A. H.; Aifantis, I.; Levine, R. L.; Ebert, B. L.
Blood (2011)

Fulltext@MSK | Save

Epigenetic effects of IDH1/IDH2 mutations

Meeting Abstract

Melnick, A. M.; Levine, R. L.; Figueroa, M. E.; Thompson, C. B.; Abdel-Wahab, O.
Blood (2011)

Fulltext@MSK | Save

Ruxolitinib, a janus kinase (JAK)-1 and-2 inhibitor modulates microrna (miR) levels in patients with myelofibrosis (MF): miR levels might predict MF treatment outcome

Meeting Abstract

Manshouri, T.; Estrov, Z.; Knez, L.; Zhang, Y.; Levine, R. L.; Kantarjian, H. M.; Verstovsek, S.
Blood (2011)

Fulltext@MSK | Save

Inhibition of AKT signaling potently inhibits the growth of JAK and MPL-mutant cells in the myeloproliferative neoplasms in vitro and in vivo

Meeting Abstract

Khan, I.; Huang, Z.; Wen, Q. J.; Koppikar, P.; Levine, R. L.; Tefferi, A.; Crispino, J.
Blood (2011)

Fulltext@MSK | Save

Final report of a phase II study of 5-azacitidine and vorinostat in patients (pts) with newly diagnosed myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) not eligible for clinical trials because poor performance and presence of other comorbidities

Meeting Abstract

Garcia-Manero, G.; Estey, E. H.; Jabbour, E.; Borthakur, G.; Kadia, T.; Naqvi, K.; Levine, R. L.; Estrov, Z.; Quintas-Cardama, A.; Konopleva, M.; more...
Blood (2011)

Fulltext@MSK | Save

Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy

Meeting Abstract

Bhagwat, N.; Koppikar, P.; Kilpivaara, O.; Manshouri, T.; Adli, M.; Mullally, A.; Abdel-Wahab, O.; Leung, L.; Weinstein, A.; Marubayashi, S.; more...
Blood (2011)

Fulltext@MSK | Save

Janus kinase-2 inhibition induces durable tolerance to alloantigen by dendritic cell-stimulated human T cells, yet preserves immunity to recall antigen

Meeting Abstract

Betts, B. C.; Abdel-Wahab, O.; Curran, S. A.; St Angelo, E. T.; Koppikar, P.; Heller, G.; Levine, R. L.; Young, J. W.
Blood (2011)

Fulltext@MSK | Save

Validation of a prognostic model and the impact of SF3B1, DNMT3A, and other mutations in 289 genetically characterized lower risk MDS patient samples

Meeting Abstract

Bejar, R.; Stevenson, K.; Caughey, B.; Abdel-Wahab, O.; Galili, N.; Garcia-Manero, G.; Kantarjian, H. M.; Raza, A.; Steensma, D. P.; Levine, R. L.; more...
Blood (2011)

Fulltext@MSK | Save